title: Comparison of plasma lipoprotein profiles and malondialdehyde between hyperlipidemia dogs with/without treatment.
abstract: BACKGROUND
  The aim of this study is to compare metabolic parameters, malondialdehyde as a lipid oxidation marker, and lipid profiles between dogs with untreated hyperlipidemia and hyperlipidemia with treatment, in order to examine the usefulness of malondialdehyde and lipid profiles as diagnostic parameters at early stages of hyperlipidemia.
  
  
  RESULTS
  Dog samples were collected from four different veterinary clinics across Japan from March to June 2013. They were separated into three groups: control, untreated hyperlipidemia based on temporally screening, and hyperlipidemia with current anti-hyperlipidemic (statins and fibrates) treatment. Triglyceride levels of untreated hyperlipidemia dogs were significantly higher than those of control dogs. ALT levels of hyperlipidemic dogs with treatment were the highest among three groups. VLDL and LDL of both cholesterol and triglyceride of untreated hyperlipidemia dogs were the highest among three groups. HDL1 levels in triglyceride of hyperlipidemia dogs with treatment were significantly higher than those of control and untreated hyperlipidemia dog. Malondialdehyde concentrations of untreated hyperlipidemia dogs were significantly higher than those of control and hyperlipidemic dogs with treatment.
  
  
  CONCLUSIONS
  In this study, dogs with untreated hyperlipidemia clearly showed abnormal lipid status, whereas hyperlipidemic dogs under anti-hyperlipidemia treatment showed more normal lipid status suggesting the effectiveness of the therapy. Anti-hyperlipidemics (statins and fibrates) for dogs are also effective in relieving elevated levels of lipids and lipid oxidation. Plasma lipid (triglyceride and cholesterol) profiles and malondialdehyde are useful diagnostic tools for identifying early stages of untreatment hyperlipidemia in dogs.
authors.forename: Gebin
authors.initials: G
authors.lastname: Li
authors.forename: Koh
authors.initials: K
authors.lastname: Kawasumi
authors.forename: Yuki
authors.initials: Y
authors.lastname: Okada
authors.forename: Shingo
authors.initials: S
authors.lastname: Ishikawa
authors.forename: Ichiro
authors.initials: I
authors.lastname: Yamamoto
authors.forename: Toshiro
authors.initials: T
authors.lastname: Arai
authors.affiliation: Department of Veterinary Bioscience, School of Veterinary Medicine, Nippon Veterinary and Life Science University, 1-7-1 Kyonancho, Musashino, Tokyo 180-8602, Japan. d0908@nvlu.ac.jp.
authors.forename: Nobuko
authors.initials: N
authors.lastname: Mori
mesh_terms: D000818:Animals; D004283:Dog Diseases / Q000097:blood* / Q000188:drug therapy; D004285:Dogs; D005260:Female; D058607:Fibric Acids / Q000627:therapeutic use; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008315:Malondialdehyde / Q000097:blood*
chemical_list: D058607:Fibric Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D008074:Lipoproteins; D008315:Malondialdehyde